GLIX5 / Hemispherian - LARVOL DELTA

First-in-class cancer therapeutics targeting the DNA Damage Response (SNO 2023) - "Hemispherian’s lead GLIX molecules, GLIX1 and GLIX5, show excellent efficacy in vivo in xenograft models, have a superior safety profile, are orally bioavailable and are blood brain barrier penetrant. GLIX efficacy against a panel of patient-derived cell lines representing a broad spectrum of pediatric and adult brain tumor diagnoses will be discussed. Taken together, these molecules have an exceptional profile for treating a broad range of cancers including cancers of the brain."

Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Pediatrics • Solid Tumor • TET2

Hemispherian raises the first tranche of a Series A to fund the development of its novel cancer therapeutics (PRNewswire) - "Hemispherian AS...is delighted to announce the closure of the first tranche of its series A1 financing round. The round raised NOK 30M (USD 2.9M). The proceeds will support the company's drug development activities, expand its preclinical pipeline and advance its lead therapeutic compounds towards clinical development.'This funding will support preclinical development of GLIX1 and GLIX5, the company's lead assets'."

Financing • Oncology